Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival

[1]  S. Welle,et al.  Genetic Deletion of Myostatin From the Heart Prevents Skeletal Muscle Atrophy in Heart Failure , 2010, Circulation.

[2]  S. Anker,et al.  Myostatin Regulator of Muscle Wasting in Heart Failure and Treatment Target for Cardiac Cachexia , 2010 .

[3]  C. Murry,et al.  Myostatin represses physiological hypertrophy of the heart and excitation–contraction coupling , 2009, The Journal of physiology.

[4]  S. Gygi,et al.  During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation , 2009, The Journal of cell biology.

[5]  C. Mammucari,et al.  Smad2 and 3 transcription factors control muscle mass in adulthood. , 2009, American journal of physiology. Cell physiology.

[6]  S. Hatakeyama,et al.  Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. , 2009, American journal of physiology. Cell physiology.

[7]  D. Beer,et al.  Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. , 2009, Neoplasia.

[8]  M. Tisdale.  Mechanisms of cancer cachexia. , 2009, Physiological reviews.

[9]  Xuan Chen,et al.  Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. , 2008, Molecular endocrinology.

[10]  M. Muscaritoli,et al.  Muscle myostatin signalling is enhanced in experimental cancer cachexia , 2008, European journal of clinical investigation.

[11]  K. Fearon.  Cancer cachexia: developing multimodal therapy for a multidimensional problem. , 2008, European journal of cancer.

[12]  M. Rudnicki,et al.  The emerging biology of satellite cells and their therapeutic potential. , 2008, Trends in molecular medicine.

[13]  A. Goldberg,et al.  FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. , 2007, Cell metabolism.

[14]  A. Goldberg,et al.  FoxO3 controls autophagy in skeletal muscle in vivo. , 2007, Cell metabolism.

[15]  M. Matzuk,et al.  Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. , 2007, Molecular human reproduction.

[16]  A. Cumano,et al.  Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells , 2006, The Journal of cell biology.

[17]  M. Matzuk,et al.  Regulation of muscle growth by multiple ligands signaling through activin type II receptors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Rando,et al.  Stem cells in postnatal myogenesis: molecular mechanisms of satellite cell quiescence, activation and replenishment. , 2005, Trends in cell biology.

[19]  Swarnali Acharyya,et al.  Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. , 2005, Cancer cell.

[20]  D. Glass,et al.  Skeletal muscle hypertrophy and atrophy signaling pathways. , 2005, The international journal of biochemistry & cell biology.

[21]  D. Lacey,et al.  Regulation of Protein Catabolism by Muscle-Specific and Cytokine-Inducible Ubiquitin Ligase E3α-II during Cancer Cachexia , 2004, Cancer Research.

[22]  T. Braun,et al.  Myostatin mutation associated with gross muscle hypertrophy in a child. , 2004, The New England journal of medicine.

[23]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[24]  S. Anderson,et al.  Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.

[25]  G. Christensen,et al.  Elevated Levels of Activin A in Heart Failure: Potential Role in Myocardial Remodeling , 2004, Circulation.

[26]  Seumas McCroskery,et al.  Myostatin negatively regulates satellite cell activation and self-renewal , 2003, The Journal of cell biology.

[27]  T. Zimmers,et al.  Induction of Cachexia in Mice by Systemically Administered Myostatin , 2002, Science.

[28]  A. Goldberg,et al.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[30]  N. Umesaki,et al.  Production of activin A in hyperplasia and adenocarcinoma of the human endometrium. , 2001, Gynecologic oncology.

[31]  J. Kleeff,et al.  Overexpression of activin A in stage IV colorectal cancer , 2001, Gut.

[32]  Se-Jin Lee,et al.  Regulation of myostatin activity and muscle growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Matzuk,et al.  Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice. , 2000, Endocrinology.

[34]  A. Mes-Masson,et al.  Characterization of four novel epithelial ovarian cancer cell lines , 2000, In Vitro Cellular & Developmental Biology - Animal.

[35]  F. López‐Soriano,et al.  The role of cytokines in cancer cachexia , 1999, Medicinal research reviews.

[36]  A. Goldberg,et al.  Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Gadducci,et al.  Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. , 1998, The Journal of clinical endocrinology and metabolism.

[38]  M. O’Bryan,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Expression and Localization of Activin Subunits and Follistatins in Tissues from Men with High Grade Prostate Cancer , 2022 .

[39]  A. Goldberg,et al.  Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. , 1996, The New England journal of medicine.

[40]  Y. Sakamoto,et al.  Serum immunoreactive activin A levels in normal subjects and patients with various diseases. , 1996, The Journal of clinical endocrinology and metabolism.

[41]  A. Bradley,et al.  Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. , 1996, Molecular endocrinology.

[42]  A. Bradley,et al.  Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Tanaka,et al.  Detection of serum cytokine levels in experimental cancer cachexia of colon 26 adenocarcinoma-bearing mice. , 1993, Cancer letters.

[44]  F. Walsh,et al.  The cell adhesion molecule M-cadherin is specifically expressed in developing and regenerating, but not denervated skeletal muscle. , 1993, Development.

[45]  G. Strassmann,et al.  Evidence for the involvement of interleukin 6 in experimental cancer cachexia. , 1992, The Journal of clinical investigation.

[46]  K. Abe,et al.  Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. , 1991, Cancer research.

[47]  H. Ishitsuka,et al.  Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. , 1990, Cancer research.

[48]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[49]  A. Mauro.  SATELLITE CELL OF SKELETAL MUSCLE FIBERS , 1961, The Journal of biophysical and biochemical cytology.

[50]  H. Hellerstein,et al.  Atrophy of the Heart: A Correlative Study of Eighty‐Five Proved Cases , 1950 .